The Federal Government has announced the listing of ravulizumab (Ultomiris®) on the Pharmaceutical Benefits Scheme (PBS) for the treatment of adults with neuromyelitis optica spectrum disorders (NMOSD). This is a historic milestone as ravulizumab is the first-ever treatment specifically for NMOSD to be included on the PBS.
MS Australia is very pleased to see that health is the number one issue in this election, with solid commitments to reduce the costs of medicine and improve access to bulk billed services in general practice.
CEO Rohan Greenland has just registered for the May 50K for the fifth consecutive year and shares the many reasons why he really loves the event.
On International Women’s Day, we look at the disproportionate effects MS has on Australian women and the research MS Australia is supporting to address it.
A new multiple sclerosis (MS) research project designed to help the brain repair itself by activating its own healing processes has been announced as part of MS Australia’s latest $5.7 million research investment.
MS Australia has committed over $5.7 million to a record number of new research grants, all addressing key MS research priorities.
MS Australia is inviting Australians with MS, their friends, family, carers, doctors, MS staff, nurses, researchers, and the broader MS community to join in the discussion to share which areas of MS research and advocacy are most important to people both directly and indirectly affected by MS.
As we barrel towards another election, CEO Rohan Greenland urges politicians to back MS Australia’s three priorities to improve the lives of people living with MS and pave the way to cures.
Launching in mid-2025, the new Australian MS app InforMS is designed to help people manage their MS, creating a “one-stop shop” to hold their health information. People living with MS explain how lived experience has shaped its design.
